

Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
5 - 7 April 2011
CCV/CICG, Geneva

Tuesday, 5 April 2011

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction H. Rees, Chair of SAGE		20 min.
09:20	Report from IVB Director - Session 1 Presentation: J.-M. Okwo-Bele, WHO, 20 min. Discussion: 50 min.	FOR INFORMATION	1 h 10 min.
10:30	Coffee/tea break	Break	30 min.
11:00	Regional priorities, major policy and implementation issues: reports from AFR, EMR, SEAR - Session 2 AFR Presentation: D. Nshimirimana, WHO, 15 min. Discussion: 25 min. EMR Presentation: N. Teleb, WHO, 15 min. Discussion: 25 min.	FOR INFORMATION AND DISCUSSION	2 h
12:20	Lunch	Break	1 h 10 min.
13:30	Regional priorities, major policy and implementation issues (contd.) - Session 2 SEAR Presentation: N. Abeysinghe, WHO, 15 min. Discussion: 25 min.		

14:10	Report from the GAVI Alliance secretariat - Session 3 Presentation: N. Schwalbe, GAVI Alliance, 15 min. Discussion: 35 min.	FOR INFORMATION	50 min.
15:00	Reports from other Advisory Committees in Immunization - Session 4 Report from the Advisory Committee of the Initiative for Vaccine Research (IVAC), P. Ndumbe, Chair of IVAC, 10 min. Discussion: 15 min.	FOR INFORMATION AND DISCUSSION	50 min.
15:25	Coffee/tea break	Break	30 min.
15:55	Reports from other Advisory Committees in Immunization (contd.) - Session 4 Report of the Global Advisory Committee on Vaccine Safety (GACVS), P. Smith, Chair of GACVS, 10 min. Discussion: 15 min.		
16:20	Pandemic and seasonal influenza vaccines - Session 5 International Health Regulations Review Committee (IHR): conclusions and recommendations, H. Fineberg, Chair of the IHR Review Committee, by telephone connection, 10 min. Discussion: 30 min. H1N1 update: - use of deployed vaccine, L. Hedman, WHO, 10 min. - epidemiology, T. Mounts, WHO, 10 min. Discussion: 10 min. SAGE Working Group on influenza vaccines and immunization. Update on process, L. Miller, Chair of Working Group, 10 min. Discussion: 10 min.	FOR INFORMATION AND DISCUSSION - Present SAGE with the key conclusions and recommendations from the IHR Review Committee with particular focus on vaccines. - Report to SAGE on the use of H1N1 deployed vaccine. - Update SAGE on the current epidemiology of H1N1 influenza. - Update SAGE on the working process of the SAGE working group on influenza vaccines and immunization and on the outcome of the 14-15 February meeting of the WG.	1 h 30 min.
17:50	Cocktail		

Wednesday, 6 April 2011

08:30	Tick-borne encephalitis - Session 6 Introduction: context and process, J. Hombach, WHO, 5 min. Disease epidemiology & burden of disease, J. Suess, Friedrich Loeffler Institute, Jena, 15 min. Discussion: 15 min. Vaccine effectiveness and safety, H. Kollaritsch, University of Vienna, 15 min. Discussion: 15 min. Draft recommendations on the use of tick-borne encephalitis vaccines, J. Eskola, SAGE, 10 min. Discussion: 45 min.	FOR DECISION -Review evidence on epidemiology and burden of tick-borne encephalitis, and on tick-borne encephalitis vaccines and their performance. -Recommendations on the use of tick-borne encephalitis vaccines leading to the publication of a vaccine position paper.	2 h
10:30	Coffee/tea break	Break	30 min.
11:00	Meningococcal meningitis vaccines - Session 7 Update on the epidemiology of meningococcal disease, N. Messonnier, CDC, member of the SAGE Working Group on meningococcal vaccines, 15 min. Availability, safety and effectiveness of conjugated meningococcal A and C vaccines, M. Ramsay, UK Health Protection Agency, member of the SAGE Working Group on meningococcal vaccines, 15 min. Availability, safety and effectiveness of serogroup B/protein meningococcal vaccines, R. Borrow, UK Health Protection Agency, 15 min. Draft recommendations on the use of meningococcal vaccines, J. Abramson, Chair of the SAGE Working Group on meningococcal vaccines, 15 min. Discussion: 1 h 30 min.	FOR DECISION -Recommendations on the use of meningococcal meningitis vaccines in different settings (endemic, non-endemic, and outbreak regions) with a view to update the WHO vaccine position paper.	2 h 30 min.
12:30	Lunch	Break	1 h

13:30	Meningococcal meningitis vaccines (contd.) - Session 7	FOR DECISION	
14:30	Rubella vaccination - Session 8 Report from the Working Group, S. Reef, CDC, member of the SAGE Working Group on rubella vaccines, 20 min. Modelling the minimum coverage required to avoid an increased risk of CRS, J. Metcalf, Oxford University, 20 min Draft recommendations on the introduction of rubella vaccine and use of combined MR vaccine, S. Reef, CDC, member of the SAGE Working Group on rubella vaccines, 20 min. Discussion: 1 h 30 min.	FOR DECISION -Propose necessary updating of WHO recommended vaccination strategies for use of rubella vaccines according to the disease control goal for rubella and congenital rubella syndrome (CRS). -The specific questions to be addressed are: What are the possible disease control goals for rubella and congenital rubella syndrome? For each goal, what are the most appropriate vaccination strategies? What is the minimum required immunization coverage that should be achieved and maintained to ensure that the introduction of rubella-containing vaccine does not increase the risk of CRS? -The recommendations from SAGE will be used to update the WHO Rubella Vaccines position paper.	2 h 30 min.
15:30	Coffee/tea break	Break	30 min.
16:00	Rubella vaccination (contd.) - Session 8		
17:30	End of day		

Thursday, 7 April 2011

08:30	Polio eradication - Session 9 Outcomes from the Independent Monitoring Board for the Global Polio Eradication Initiative, L. Donaldson, Chair of the Independent Monitoring Board, by telephone connection, 10 min. Discussion: 20 min. New breakthroughs in assuring affordable IPV options for low-income countries in the post-eradication era, R. Sutter, WHO, 10 min. Discussion: 20 min. SAGE IPV Working Group: potential pre-requisites if cessation of type-2 oral poliovirus vaccine is to be considered before global certification, E. Miller, Chair of the SAGE IPV Working Group, 10 min. Discussion: 20 min.	FOR INFORMATION AND DISCUSSION -This is mostly for information of SAGE on: - the deliberations of the Independent Monitoring Board for the Global Polio Eradication Initiative - recent advances in the research agenda towards assuring safe and affordable IPV for possible post-eradication polio vaccination options. -SAGE will also be requested to discuss and endorse the potential pre-requisites for pre-certification cessation of type-2 oral poliovirus vaccine use as proposed by the SAGE IPV Working Group.	1 h 30 min.
10:00	Coffee/tea break	Break	30 min.
10:30	Update on evidence-based review process and GRADing of quality of scientific evidence - Session 10 Update from the SAGE discussion group, D. Durrheim, SAGE, 15 min. Discussion: 45 min.	FOR INFORMATION AND DISCUSSION -Present SAGE with a draft paper on the development of evidence-based recommendations on vaccine use. -Present SAGE with the proposed adjustments to the scoring of quality of scientific evidence and use of GRADE tables and get SAGE comments on those adjustments.	1 h
11:30	Cholera vaccine: feed-back on implementation of SAGE recommendations - Session 11 Use of cholera vaccine in countries: progress and challenges, P. Namgyal, WHO, 10 min. Challenges of use of cholera vaccine in Haiti, C. Ruiz-Matus, WHO, 10 min. Investment case for accelerated introduction of cholera vaccines, B. Maskery, International Vaccine Institute, 20 min. Discussion: 40 min.	FOR INFORMATION AND DISCUSSION -Provide feed-back on the progress and challenges for countries to implement SAGE recommendations on the use of cholera vaccine. -Present the investment case for the accelerated introduction of oral cholera vaccines prepared by the International Vaccine Institute.	1 h 20 min.
12:50	Closing		20 min.
13:10	End of meeting		